Steroid sidestep: Evading androgen ablation by abiraterone

Nima Sharifi

Research output: Contribution to journalArticle

1 Scopus citations


Tumor mechanisms of abiraterone resistance in clinical prostate cancer are not well defined. Chen and colleagues report that a T878A androgen receptor mutation occurs in a subset of patients progressing while receiving abiraterone, suggesting that this may be a therapeutically exploitable mechanism of abiraterone resistance in castration-resistant prostate cancer.

Original languageEnglish (US)
Pages (from-to)1240-1242
Number of pages3
JournalClinical Cancer Research
Issue number6
Publication statusPublished - Mar 15 2015


ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this